All ACS (including AMI): 4 trials - ATLAS ACS 2 - TIMI 51 (2.5mg) - ATLAS ACS 2 - TIMI 51 (5mg) - ATLAS ACS-TIMI 46 (2.5mg) - ATLAS ACS-TIMI 46 (5mg)
All type of patients: 4 trials - ATLAS ACS 2 - TIMI 51 (2.5mg) - ATLAS ACS 2 - TIMI 51 (5mg) - ATLAS ACS-TIMI 46 (2.5mg) - ATLAS ACS-TIMI 46 (5mg)
Patients with a recent ACS: 2 trials - ATLAS ACS 2 - TIMI 51 (2.5mg) - ATLAS ACS 2 - TIMI 51 (5mg)
All type of patients : 2 trials - ROCKET-AF - ROCKET J
Primary prevention of thromboembolic events: 2 trials - ROCKET-AF - ROCKET J
Secondary prevention of thromboembolic events: 1 trials - ROCKET (2nd prevention subgroup)
All type of patients: 2 trials - COMPASS (rivaroxaban + aspirin) - COMPASS (rivaroxaban alone)
Secondary prevention: 2 trials - COMPASS (rivaroxaban + aspirin) - COMPASS (rivaroxaban alone)
All type of patients: 1 trials - COMMANDER HF
1 trials - Einstein-PE Evaluation
elective major knee surgery : 3 trials - RECORD 4 - RECORD 3 - ODIXa-KNEE
All type of patients : 6 trials - RECORD 4 - RECORD 1 - RECORD 2 - RECORD 3 - ODIXa-HIP 10mg - ODIXa-KNEE
Elective hip replacement: 3 trials - RECORD 1 - RECORD 2 - ODIXa-HIP 10mg
Elective major knee surgery : 3 trials - RECORD 4 - RECORD 3 - ODIXa-KNEE
Medical patients: 1 trials - MARINER
Orthopaedic surgery: 6 trials - RECORD 4 - RECORD 1 - RECORD 2 - RECORD 3 - ODIXa-HIP 10mg - ODIXa-KNEE
Orthopedic surgery: 6 trials - RECORD 4 - RECORD 1 - RECORD 2 - RECORD 3 - ODIXa-HIP 10mg - ODIXa-KNEE
secondary prevention of VTE : 1 trials - EINSTEIN-extension
All type of patients: 4 trials - Einstein-PE Evaluation - Einstein-DVT Evaluation - EINSTEIN-extension - Einstein-DVT Dose-Ranging Study
All types of patients: 4 trials - Einstein-PE Evaluation - Einstein-DVT Evaluation - EINSTEIN-extension - Einstein-DVT Dose-Ranging Study
Patients with cancer: 4 trials - SELECT D - EINSTEIN (subgroup) - CASTA-DIVA - CONKO-011
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
